Is PhaseBio Pharmaceuticals Inc (PHAS) Stock a Bad Value?

Monday, April 18, 2022 01:30 PM | InvestorsObserver Analysts

Mentioned in this article

Is PhaseBio Pharmaceuticals Inc (PHAS) Stock a Bad Value?

PhaseBio Pharmaceuticals Inc (PHAS) stock is down -61.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives PHAS stock a score of 34 out of a possible 100.

That rank is chiefly influenced by a short-term technical score of 13. PHAS's rank also includes a long-term technical score of 18. The fundamental score for PHAS is 70. In addition to the average rating from Wall Street analysts, PHAS stock has a mean target price of $16.00. This means analysts expect the stock to climb 1200.81% over the next 12 months.

PHAS has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on PHAS!

See Full PHAS Report

What's Happening with PHAS Stock Today

PhaseBio Pharmaceuticals Inc (PHAS) stock has fallen -3.15% while the S&P 500 is down -0.15% as of 1:24 PM on Monday, Apr 18. PHAS is down -$0.04 from the previous closing price of $1.27 on volume of 136,768 shares. Over the past year the S&P 500 has risen 5.35% while PHAS is down -61.44%. PHAS lost -$2.98 per share in the over the last 12 months. Click Here to get the full Stock Report for PhaseBio Pharmaceuticals Inc stock.